{"id":12914,"date":"2026-08-14T14:24:03","date_gmt":"2026-08-14T14:24:03","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=12914"},"modified":"2026-08-14T14:31:56","modified_gmt":"2026-08-14T14:31:56","slug":"relfydess-botox-alternative-you-dont-reconstitute","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/relfydess-botox-alternative-you-dont-reconstitute\/","title":{"rendered":"Relfydess: Botox Alternative You Don’t Reconstitute"},"content":{"rendered":"\n

One vial, one patient, one session, and whatever is left goes in the bin. That rule sits in the licence for Relfydess 1.5ml Single Vial (100units\/ml)<\/mark><\/a>, and it changes how the product should be priced. A vial holds 150 units. Treating the glabella uses 50. Relfydess<\/mark><\/a> is the first ready-to-use liquid toxin of its molecule licensed for use in the UK, and aesthetic clinics<\/mark><\/a> assessing it on cost per unit against a powdered toxin will reach the wrong answer before anyone has been injected.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Relfydess UK Licence: What It Covers and Who It Excludes<\/h2>\n\n\n\n

The UK marketing authorisation covers moderate to severe glabellar lines and moderate to severe lateral canthal lines, in adults under 65, where those lines have an important psychological impact on the patient. Both areas arrived on the licence together, which is unusual for a new neuromodulator entering the market.<\/p>\n\n\n\n

Two boundaries follow from that wording and get missed. The upper age limit is 65, so a 68-year-old requesting frown line treatment is off-label regardless of skin quality or muscle bulk. And forehead lines are not on the licence, which matters because most patients presenting for “Botox” expect the forehead treated as part of the same appointment.<\/p>\n\n\n\n

The active is relabotulinumtoxinA, a highly purified type A neurotoxin manufactured without the complexing proteins carried by conventional preparations. It works the way every type A toxin<\/mark><\/a> works, by cleaving SNAP-25 and blocking acetylcholine release at the neuromuscular junction. The difference is upstream, in a purification and stabilisation process that keeps the molecule intact in liquid rather than requiring it to be freeze-dried and rehydrated.<\/p>\n\n\n\n

Relfydess Dosing, Injection Points and Volumes<\/h2>\n\n\n\n

The Relfydess Summary of Product Characteristics<\/mark><\/a> sets the glabellar dose at 50 units in 0.5 mL, given as 10 units in 0.1 mL at each of five intramuscular sites: two into each corrugator and one into the procerus near the nasofrontal angle. Landmarks are easier to identify if palpated and observed at maximum frown.<\/p>\n\n\n\n

Lateral canthal lines take 60 units in 0.6 mL, again 10 units in 0.1 mL per site, across six sites with three per side. Treating both areas in one session comes to 110 units in 1.1 mL.<\/p>\n\n\n\n

The volume per point deserves attention. At a fixed 100 units per mL, every injection delivers 0.1 mL. Practitioners accustomed to reconstituting powder to a concentration of their own choosing lose that lever. A high-dilution injector who has built a technique around wider spread, and a low-dilution injector who relies on tight placement, both have to adapt to a volume that is now fixed.<\/p>\n\n\n\n

Treatment interval is a minimum of 12 weeks. Repeat treatment beyond 12 months has not been evaluated.<\/p>\n\n\n\n

Contraindications and the cautions that get overlooked<\/h3>\n\n\n\n

Absolute contraindications are known hypersensitivity to any botulinum toxin<\/mark><\/a> product or excipient, infection at the proposed injection sites, and myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis. The neuromuscular conditions are worth asking about directly rather than relying on a patient to volunteer them, since many people do not connect a neurological diagnosis to a cosmetic appointment.<\/p>\n\n\n\n

Relfydess must not be injected into a blood vessel, and is not recommended in patients with prolonged bleeding time. Patients treated at recommended doses may still experience exaggerated muscle weakness. The vial contains 1.6 mg of polysorbate 80, which is a genuine consideration for the small number of patients with a polysorbate allergy.<\/p>\n\n\n\n

A practitioner meeting an unfamiliar reaction at 7pm on a Saturday needs a medical opinion in minutes, not an email answered on Monday, and 24\/7 aesthetic complications support<\/mark><\/a> exists for exactly that gap. Non-medic injectors in particular should have that route confirmed before adding any toxin they have not worked with.<\/p>\n\n\n\n

\"Practitioner<\/figure>\n\n\n\n

Relfydess 1.5ml Single Vial: Building a Menu Around One Vial<\/h2>\n\n\n\n

Those 110 units against a 150-unit vial are the figure that matters commercially. The vial is sized for the patient having both licensed areas treated together, not the frown-lines-only patient, and a clinic that mostly sells single-area toxin will be discarding two-thirds of every unit it pays for.<\/p>\n\n\n\n

The practical answer is menu design. Price the combined upper face as one treatment rather than two line items, and the cost per patient starts to make sense against what the clinic charges. Practitioners who buy Relfydess 1.5ml Single Vial online<\/mark><\/a> without adjusting the menu are absorbing the wastage into margin instead of designing around it.<\/p>\n\n\n\n

Scheduling changes too. Clinics used to clustering toxin appointments to get value out of a reconstituted vial gain nothing from doing that here, since no vial carries across patients. Booking three toxin patients on the same afternoon costs three vials regardless of how close together they sit.<\/p>\n\n\n\n

Storage is 2-8\u00b0C in the original carton, protected from light. Cold chain ordering has its own timing constraints, and a vial delivered on a Friday afternoon to an empty clinic is a vial at risk.<\/p>\n\n\n\n

Relfydess vs Botox: What Actually Changes at the Chairside<\/h2>\n\n\n\n

Preparation is the obvious difference. No saline, no reconstitution, no variation between one practitioner’s dilution and another’s. Onset is the more interesting one: median time to effect is 2 to 3 days, with some patients reporting a change within a day, and effect has been demonstrated at six months with up to 75% of patients not back to baseline.<\/p>\n\n\n\n

Against that, Botox<\/mark><\/a> holds a far broader UK licence that includes forehead lines, and carries decades of published off-label practice across the mid and lower face that a newer molecule has not yet accumulated. A practitioner whose treatment plans routinely extend beyond the two licensed Relfydess areas will still need a second toxin on the shelf.<\/p>\n\n\n\n

The unit trap is where harm happens. Relfydess units are not interchangeable with Botox units, Speywood units, or any other preparation, and there is no conversion factor. A practitioner used to drawing 20 units for a glabella and reading 50 on this label may assume the product is weaker. It is a different scale, not a weaker one. Anyone stocking a new toxin should be reading its own dosing table rather than adapting a familiar one, and the supply chain rules set out in how to buy Botox legally in the UK<\/mark><\/a> apply identically to every prescription-only toxin, this one included.<\/p>\n\n\n\n

Relfydess vs Alluzience: Two Liquids, Two Different Molecules<\/h2>\n\n\n\n

Both are ready-to-use liquids, and both reach UK clinics through Galderma, which is where practitioners tend to assume the similarity runs deeper than it does. Relfydess is relabotulinumtoxinA. Alluzience, the UK’s first liquid toxin<\/mark><\/a>, is abobotulinumtoxinA dosed in Speywood units, the same active as Azzalure in a pre-mixed presentation.<\/p>\n\n\n\n

The numbers look deceptively alike. Both use 50 units for the glabella, split as 10 units across five points. The volumes are not alike at all. Alluzience<\/mark><\/a> sits at 200 Speywood units per mL, so 10 units is 0.05 mL. Relfydess sits at 100 units per mL, so 10 units is 0.1 mL. Same unit count on paper, twice the injected volume per point in practice, with the diffusion implications that carries.<\/p>\n\n\n\n

Vial sizes diverge too: 125 Speywood units in 0.625 mL against 150 units in 1.5 mL. Practitioners weighing choosing between Alluzience and Azzalure<\/mark><\/a> are comparing two presentations of one molecule. Comparing either to Relfydess is comparing two different drugs, and the Alluzience Summary of Product Characteristics<\/mark><\/a> should be read alongside rather than assumed to transfer.<\/p>\n\n\n\n

Relfydess Reviews: What Practitioners Are Reporting So Far<\/h2>\n\n\n\n

Early UK feedback centres on three things. Preparation time drops, which matters most in high-volume clinics running back-to-back toxin appointments. Onset is genuinely quicker than practitioners expect, which changes the follow-up conversation, since a patient told to wait two weeks may return convinced nothing happened when in fact the effect appeared on day two and they stopped watching. And the fixed concentration removes an argument, which experienced injectors either welcome or resent depending on how much of their technique rests on dilution.<\/p>\n\n\n\n

Patient-facing Relfydess Botox reviews should be read with the usual caution. Most were written inside the first fortnight of a treatment whose duration data runs to six months, and a review posted at day ten says almost nothing about whether the result held. Aftercare advice does not change materially from what is set out in Botox aftercare guidance for patients<\/mark><\/a>, and clinics already using a standard toxin aftercare form can carry it across with the product name updated.<\/p>\n\n\n\n

Relfydess Botox Price: Cost Per Patient, Not Cost Per Unit<\/h2>\n\n\n\n

Trade pricing on Faces sits behind login and requires an active prescriber connection, so figures quoted publicly elsewhere are not the ones a given clinic will pay. The useful exercise is calculating cost per treated patient rather than cost per unit, then running that number against a combined glabellar and crow’s feet price rather than a glabellar-only price. The product’s commercial case becomes clear or it doesn’t, and either answer is worth having before ordering.<\/p>\n\n\n\n

How patients are searching for it<\/h3>\n\n\n\n

Search behaviour is running ahead of clinic adoption. Terms like Relfydess Botox Essex and Relfydess wrinkle relaxing injections near me are being typed by patients who have read about a new liquid toxin and want to know who near them offers it. Clinics that have stocked it and said so on a claimed aesthetic clinic directory<\/mark><\/a> listing are the ones those searches find.<\/p>\n\n\n\n

Anything said publicly still sits under prescription-only medicine advertising restrictions, and the rules on advertising Botox in the UK<\/mark><\/a> apply to this product without modification. Naming the drug in patient-facing promotion is the line practitioners most often cross without realising.<\/p>\n\n\n\n

Relfydess 1.5ml Single Vial: Order via a Prescriber First<\/h2>\n\n\n\n

Toxin ordering runs prescriber<\/mark><\/a> first, basket second. Connect with a prescriber on Faces, and the Relfydess 1.5ml Single Vial price<\/mark><\/a> becomes visible for your clinic, with cold chain delivery scheduled so vials don’t sit over a weekend.<\/p>\n\n\n\n

FAQs<\/strong><\/h2>\n\n\n
\n
\n
\n

What is Relfydess?<\/strong><\/p>\n

\n\n

Relfydess is a ready-to-use liquid botulinum toxin type A, licensed in the UK for moderate to severe glabellar lines and lateral canthal lines in adults under 65. The active is relabotulinumtoxinA, supplied at 100 units per mL in a 1.5 mL vial and injected without reconstitution, which distinguishes it from powdered toxins that require mixing with saline before use.<\/p>\n\n<\/div>\n<\/div>\n

\n

How long does Relfydess take to work?<\/strong><\/p>\n

\n\n

Median time to onset is 2 to 3 days, with some patients reporting an effect within 24 hours. Effect has been demonstrated for six months, with up to 75% of patients not returning to baseline over that period. Patients should be told to expect early movement rather than waiting a fortnight, and follow-up review should be scheduled with the faster onset in mind.<\/p>\n\n<\/div>\n<\/div>\n

\n

Can a patient switch from Botox to Relfydess?<\/strong><\/p>\n

\n\n

Yes, and no washout period is specified. What matters is that the dose comes from the Relfydess table rather than being converted from the patient’s previous Botox units, because no conversion factor exists between the two. Treat the last toxin appointment as the start of the minimum 12-week interval, and reassess muscle bulk and line severity at consultation rather than replicating the previous treatment plan on a new product.<\/p>\n\n<\/div>\n<\/div>\n

\n

Can Relfydess be used on the forehead?<\/strong><\/p>\n

\n\n

Not within its UK licence, which covers glabellar and lateral canthal lines only. Frontalis treatment is off-label, which is a decision for the prescriber to take and record, with the off-label use documented on the consent form and checked against the practitioner’s indemnity cover. There is also no published dosing table for the frontalis with this product, so a practitioner is extrapolating, and the fixed 0.1 mL per injection point carries more risk of spread onto the brow here than it does in the glabella. Practitioners should confirm the current licensed Relfydess treatment areas<\/a> before planning any area beyond the two on the label.<\/p>\n\n<\/div>\n<\/div>\n

\n

Who can buy Relfydess in the UK?<\/strong><\/p>\n

\n\n

Only a practitioner working with a prescriber, through a GPhC-registered pharmacy, against a prescription written for a named patient after an adequate assessment. Relfydess is a prescription-only medicine, so non-prescribing injectors cannot hold speculative stock, and no legitimate supplier will sell it without a prescription attached. Practitioners without an existing arrangement can find a prescriber near you<\/a> before ordering.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

One vial, one patient, one session, and whatever is left goes in the bin. That rule sits in the licence for Relfydess 1.5ml Single Vial (100units\/ml), and it changes how the product should be priced. A vial holds 150 units. Treating the glabella uses 50. Relfydess is the first ready-to-use liquid toxin of its molecule […]<\/p>\n","protected":false},"author":6,"featured_media":12917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[20],"tags":[12,10,1065,306,227],"class_list":["post-12914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aesthetics","tag-aesthetics","tag-medical-practitioners","tag-relfydess","tag-toxin","tag-uk"],"_links":{"self":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/comments?post=12914"}],"version-history":[{"count":2,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12914\/revisions"}],"predecessor-version":[{"id":12919,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12914\/revisions\/12919"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media\/12917"}],"wp:attachment":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media?parent=12914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/categories?post=12914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/tags?post=12914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}